



Early View

Research letter

Longitudinal changes in airway hyperresponsiveness and COPD mortality

Andreas A. Teferra, Judith M. Vonk, H. Marike Boezen

Please cite this article as: Teferra AA, Vonk JM, Boezen HM. Longitudinal changes in airway hyperresponsiveness and COPD mortality. *Eur Respir J* 2019; in press (<https://doi.org/10.1183/13993003.01378-2019>).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Longitudinal changes in airway hyperresponsiveness and COPD mortality

Andreas A. Teferra^{1,2,3}, Judith M. Vonk^{1,2}, H. Marike Boezen^{1,2}

¹University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands

²Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

³Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio, USA

Correspondence address:

H. Marike Boezen

Department of Epidemiology

University of Groningen, University Medical Center Groningen

Hanzeplein 1, 9700 RB

Groningen, the Netherlands

h.m.boezen@umcg.nl

To the Editor:

Airway hyperresponsiveness (AHR) is associated with an increased mortality risk among men [1] and COPD patients [2]. However, this association is largely based on cross-sectional studies using a single measurement of AHR to predict mortality; inherently ignoring the longitudinal variability of AHR. AHR is variable regardless of disease or medication status, and is linked with changes in smoking habits, seasonal variations and exposure to pollutants [3–5]. Considering this, it remains unclear how changes in AHR affect mortality, specifically from causes such as COPD, cardiovascular disease (CVD) and cancer.

We used data from the Vlagtwedde-Vlaardingen study (1965 to 1990) [6], a general population-based cohort of two communities in the Netherlands followed-up every three years. At all visits, AHR was measured with histamine biphosphate administered in increasing doses of 1, 4, 8, 16 and 32 mg/ml for 30 seconds followed by lung function measurements. The provocation concentration (PC₁₀) which caused a steady reduction in inspiratory vital capacity (IVC) or forced expiratory volume in one second (FEV₁) of more than 10% compared to baseline was then considered as the threshold value. Data on weight, height, eosinophil count, smoking habits and respiratory symptoms were also collected at each follow-up period. Vital status of all participants including specific causes of death was updated on December 31st, 2016 at Statistics Netherlands (The Hague, the Netherlands). The causes of death were coded according to the International Classification of Diseases (ICD) (versions 7-10).

We classified AHR based on histamine threshold, with ≤ 8 mg/ml indicating positive AHR (responders) and > 8 mg/ml indicating negative AHR (non-responders) [7]. We then included subjects who had a minimum of two AHR measurements and categorized changes in AHR from baseline (first available measurement) to the last available measurement for each subject as: *never AHR* (if subjects were non-hyperresponsive at baseline and during follow-up), *persistent AHR* (if subjects were hyperresponsive at baseline and during follow-up), *remitting AHR* (if subjects were hyperresponsive at baseline but became non-hyperresponsive during follow-up), *developing AHR* (if subjects were non-hyperresponsive at baseline but became hyperresponsive during follow-up), and *variable AHR* (if subjects did not have a specific trend in AHR, constituting all remaining subjects). We calculated subject-specific annual change estimates for continuous variables (BMI, FEV₁, FEV₁/IVC and eosinophil count) by taking the difference between the last and first available measurements and standardizing this based on the number of years of follow-up. Changes in smoking and dyspnea were used as previously defined [8,9]. Asthma attacks were self-reported attacks of shortness of breath with wheezing in any of the visits.

The association between changes in AHR and all-cause and cause-specific mortality was estimated with Cox proportional-hazards model. The time to event was defined from the last available AHR measurement until the date of death or censoring on December 31, 2016. We adjusted for lung function by including both baseline FEV₁ and the yearly change estimate of FEV₁ in the model. We also adjusted for other fixed (gender, place of residence, baseline age) and changing covariates (BMI, eosinophil count, smoking status, dyspnea and asthma attacks). For cause-specific mortality, subjects who died from causes other than the cause of interest were censored at the age of death and a competing risk analysis was performed [10]. Subjects who died due to external causes of death such as accidents and suicides were excluded from the analysis (n=18).

In total, 1,464 subjects had at least two AHR measurements. Among these, 702 (47.9%) had died by the end of December 31st, 2016 and only 9 (0.6%) were lost to follow-up (Table 1). Among those who died, 28 (3.9%) died of COPD, 235 (32.6%) died of CVD, and 255 (35.4%) died due to cancer. Deceased subjects had a higher prevalence of AHR, were more often smokers and had lower lung function levels at baseline. Subjects who died of COPD had more AHR at baseline (35.7%) than those who died of CVD (13.6%) or cancer (10.2%).

In the adjusted model, none of the four AHR-change categories, compared to never AHR, showed a statistically significant association with all-cause mortality. However, the adjusted cause-specific survival analysis showed a statistically significant association between changes in AHR and COPD mortality. Subjects with persistent AHR or variable AHR had a higher risk of dying of COPD

compared to those who were never hyperresponsive. Specifically, throughout the observation period, subjects with persistent AHR were six times more likely to die of COPD (HR: 6.07, 95% CI: 1.23-29.92) and those with variable AHR were four times more likely to die of COPD (HR: 4.56, 95% CI: 1.2-17.24), both compared to those who never had AHR (Table 1). We did not observe a significant association between changes in AHR and CVD or cancer mortality.

Cockcroft and Davis [11] classified components of AHR as persistent and transient, reflecting airway remodelling and airway inflammation respectively. In our study, subjects with persistent AHR likely had irreversible airway remodelling. Repetitive stimuli and a constant activation of the repair process are mechanisms behind airway remodelling in COPD leading to airway wall thickening, decrease in airway lumen size and reduced airflow [12,13]. These mechanisms can accelerate the progress of COPD and lead to premature death. Individuals with variable AHR likely present the transient component of AHR characterized by airway inflammation [11]. This independence of airway restructuring and airway inflammation in COPD [14] suggests potentially distinct pathophysiologic mechanisms behind individuals with persistent AHR and variable AHR.

Clinical management of airway inflammation may possibly 'normalize' AHR and lower long-term mortality risk from COPD but future studies should be performed to investigate this. In our study, subjects with remitting AHR did not have a higher risk of COPD mortality compared to the never AHR. This suggests that 'losing' AHR over time can have a favourable outcome on the risk of COPD death, and possibly indicates the gradual attenuation of airway inflammation in some individuals [15]. This improvement of AHR can also be related to lifestyle changes including smoking cessation and use of medications to manage asthmatic symptoms. Compared to those who died of CVD or cancer, subjects who died from COPD had a higher prevalence of asthmatic symptoms (wheezing and asthma attack) at baseline.

A major strength of our study is the extensive follow-up with minimal attrition and the use of objective and standardized measurements. People with low lung function levels ($FEV_1 < 1.5$ litres) were excluded from AHR measurements. This is important to note since reduced FEV_1 is related to mortality and AHR, indicating that the results are best generalizable to those with good lung health. Although histamine provocation is no longer commonly used due to its adverse effects, it is very similar to a methacholine bronchoprovocation test [16]. A $PC_{10} \leq 8$ mg/ml in the 30 seconds protocol used in our study is comparable to a $PC_{20} \leq 4$ mg/ml in the 2 minutes protocol, which is the recommended cutpoint for positive AHR [17]. We were not able to control for other possible confounders such as medication status and use of inhaled corticosteroids (which are shown to influence both AHR and COPD mortality), clinical data on lung phenotypes, airway calibre,

occupational exposure, and ambient air pollution. Finally, the use of administrative data for outcome assessment might have introduced some misclassification bias on the causes of death.

With a longitudinal cohort accruing 51 years of follow-up, repeated AHR measurements and control for previously suggested confounders such as lung function and smoking [18], we show that AHR that is present at all occasions (persistent) or some occasions but not always (variable) is associated with a higher risk of COPD mortality. Early targeting of individuals who display AHR on multiple occasions or those with varying AHR measurements could be an important step in reducing COPD related deaths.

Table 1: Characteristics of the participants classified by changes in AHR

	Never AHR n=850 (58.1%)	Always AHR n=41 (2.8%)	Remitting AHR n=41 (28%)	Developing AHR n=357 (24.4%)	Variable AHR n=175 (12.0%)
Male, <i>n (%)</i>	479 (56.4)	25 (61.0)	23 (56.1)	215 (60.2)	104 (59.4)
Baseline age, <i>mean (SD)</i>	35.5 (10.9)	43.9 (10.1)	42.4 (12.1)	38.8 (10.7)	37.7 (10.7)
Baseline BMI, <i>mean (SD)</i>	24.9 (3.5)	26.4 (4.1)	26.3 (3.9)	25.6 (3.3)	25.6 (2.7)
Baseline FEV ₁ (L), <i>mean (SD)</i>	3.38 (0.75)	2.52 (0.67)	2.67 (0.80)	3.13 (0.66)	3.08 (0.76)
Baseline FEV1/IVC (%), <i>mean (SD)</i>	79.94 (6.73)	67.57 (11.61)	72.29 (6.57)	76.32 (7.63)	75.31 (8.92)
Baseline smoking status, <i>n (%)</i>					
never	272 (33.3)	8 (20.5)	12 (29.3)	93 (27.0)	54 (31.6)
ex	130 (15.9)	5 (12.8)	5 (12.2)	47 (13.6)	16 (9.4)
current	415 (50.8)	26 (66.7)	24 (58.5)	205 (59.4)	101 (59.1)
Annual change in BMI, <i>mean (SD)</i>	0.1 (0.2)	0.1 (0.2)	0.1 (0.3)	0.1 (0.2)	0.1 (0.2)
Annual change in FEV1 (ml/year), <i>mean (SD)</i>	-19.3 (39.2)	-34.7 (31.0)	5.8 (107.6)	-30.7 (28.7)	-22.7 (22.9)
Annual change in FEV1/IVC (%/year), <i>mean (SD)</i>	-0.22 (0.70)	-0.49 (0.88)	0.08 (1.04)	-0.34 (0.58)	-0.17 (0.45)
Change in smoking status, <i>n (%)</i>					
Persistent never	229 (27.3)	7 (17.9)	11 (26.8)	77 (22.0)	45 (25.9)
Persistent ex	139 (16.6)	5 (12.8)	6 (14.6)	47 (13.4)	22 (12.6)
Persistent current	247 (29.4)	13 (33.3)	15 (36.6)	135 (38.6)	52 (29.9)
Quitter	136 (16.2)	9 (23.1)	8 (19.5)	52 (14.9)	38 (21.8)
(Re-)Starter	34 (4.1)	2 (5.1)	0 (0.0)	14 (4.0)	6 (3.4)
Unstructured	54 (6.4)	3 (7.7)	1 (2.4)	25 (7.1)	11 (6.3)
Vital status, <i>n (%)</i>					
Alive	479 (56.4)	9 (22.0)	14 (34.1)	169 (47.3)	82 (46.9)
Dead	365 (42.9)	32 (78.0)	27 (65.9)	185 (51.8)	93 (53.1)
Unknown	6 (0.7)	0 (0.0)	0 (0.0)	3 (0.8)	0 (0.0)
Causes of death, <i>n (%)</i>					
COPD	8 (2.2)	6 (18.8)	3 (11.1)	5 (2.7)	6 (6.5)
CVD	120 (32.9)	11 (34.4)	9 (33.3)	64 (34.6)	31 (33.3)
Cancer	139 (38.1)	6 (18.8)	9 (33.3)	71 (38.4)	30 (32.3)
Other	98 (26.8)	9 (28.1)	6 (22.2)	45 (24.3)	26 (28.0)
Hazard Ratios, <i>HR (95% CI)</i> [*]					
All	1.00	0.96 (0.63-1.46)	0.95 (0.62-1.45)	0.95 (0.78-1.17)	1.18 (0.91-1.51)
COPD	1.00	6.07 (1.23-29.92)	1.35 (0.23-7.83)	1.05 (0.26-4.15)	4.56 (1.20-17.24)
CVD	1.00	1.09 (0.53-2.24)	0.80 (0.38-1.72)	1.07 (0.75-1.50)	0.85 (0.60-1.19)
Cancer	1.00	0.47 (0.19-1.14)	0.90 (0.44-1.84)	0.85 (0.60-1.19)	0.92 (0.59-1.42)

*Never AHR (reference)

Acknowledgements

The authors would like to thank Statistics Netherlands (CBS) for providing access to vital status data for the participants. We also want to thank Dr. Douwe Postmus (Department of Epidemiology, University of Groningen) and Hans Burgerhof, MSc (Department of Epidemiology, University of Groningen) for providing valuable statistical advice.

References

1. Becker EC, Wölke G, Heinrich J. Bronchial responsiveness, spirometry and mortality in a cohort of adults. *J Asthma*. 2013 May;50(4):427–32.
2. Hoppers JJ, Postma DS, Rijcken B, Weiss ST, Schouten JP. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. *Lancet*. 2000 Oct;356(9238):1313–7.
3. Redline S, Tager IB, Speizer FE, Rosner B, Weiss ST. Longitudinal variability in airway responsiveness in a population-based sample of children and young adults. Intrinsic and extrinsic contributing factors. *Am Rev Respir Dis*. 1989;140(1):172–8.
4. Rijcken B, Schouten JP, Weiss ST, Rosner B, De Vries K, Van der Lende R. Long-term variability of bronchial responsiveness to histamine in a random population sample of adults. *Am Rev Respir Dis*. 1993 Oct;148(4 Pt 1):944–9.
5. Chinn S, Jarvis D, Luczynska CM, Ackermann-Liebrich U, Antó JM, Cerveri I, et al. An increase in bronchial responsiveness is associated with continuing or restarting smoking. *Am J Respir Crit Care Med*. 2005;172(8):956–61.
6. Van der Lende R. Epidemiology of chronic non-specific lung disease (chronic bronchitis). University of Groningen; 1969.
7. Xu X, Rijcken B, Schouten JP, Weiss ST. Airways responsiveness and development and remission of chronic respiratory symptoms in adults. *Lancet*. 1997;350(9089):1431–4.
8. Taghizadeh N, Vonk JM, Boezen HM. Lifetime smoking history and cause-specific mortality in a cohort study with 43 years of Follow-up. *PLoS One*. 2016;11(4):1–18.
9. Figarska SM, Boezen HM, Vonk JM. Dyspnea severity, changes in dyspnea status and mortality in the general population: the Vlagtwedde/Vlaardingen study. *Eur J Epidemiol*. 2012 Nov 7;27(11):867–76.
10. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state

models. *Stat Med*. 2007 May;26(11):2389–430.

11. Cockcroft DW, Davis BE. Mechanisms of airway hyperresponsiveness. *J Allergy Clin Immunol*. 2006;118(3):551–9.
12. Hirota N, Martin JG. Mechanisms of airway remodeling. *Chest*. 2013;144(3):1026–32.
13. Ganesan S, Sajjan US. Repair and remodeling of airway epithelium after injury in chronic obstructive pulmonary disease. *Curr Respir Care Rep*. 2013;2(3):145–54.
14. Lapperre TS, Snoeck-Stroband JB, Gosman MME, Stolk J, Sont JK, Jansen DF, et al. Dissociation of Lung Function and Airway Inflammation in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. 2004 Sep 20;170(5):499–504.
15. Barnes N. Reducing inflammation in COPD: the evidence builds. *Thorax*. 2007 Nov;62(11):927–8.
16. Cockcroft D, Davis B. Direct and indirect challenges in the clinical assessment of asthma. *Ann Allergy Asthma Immunol*. 2009 Nov;103(5):363-372,400.
17. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. Guidelines for Methacholine and Exercise Challenge Testing - 1999. *Am J Respir Crit Care Med*. 2000 Jan 14;161(1):309–29.
18. Vestbo J, Hansen EF. Airway Hyperresponsiveness and COPD Mortality. *Thorax*. 2001;56(Suppl 2):11–4.